Dec. 12 (Bloomberg) -- Biogen Idec Inc., the maker of the multiple sclerosis drug Tysabri, plunged 28 percent in extended New York trading after the biotechnology company said it didn’t get any ``definitive’’ takeover offers.
Dec. 12 (Bloomberg) -- Biogen Idec Inc., the maker of the multiple sclerosis drug Tysabri, plunged 28 percent in extended New York trading after the biotechnology company said it didn’t get any ``definitive’’ takeover offers.
